Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (GB:0HJ7)
LSE:0HJ7
0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe EVANGELINE trial's simplified design is aimed at accelerating data readouts and reducing study costs, representing a financially disciplined shift in Atossa's clinical development plans.
Financial StrategyReducing the total patient count in the trial is expected to save an estimated $9-11 million in costs, thereby extending the company's cash runway and allowing greater focus on NDA-enabling work.
Regulatory FeedbackPositive recent FDA feedback supports a proposed dose-optimization trial for endoxifen that could potentially serve as a registration study.
Bears Say
Revenue RiskA revenue risk adjustment of 70% is factored in based on clinical trial risk and stage of development.
Atossa Therapeutics News
0HJ7 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 29 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.058 by -$0.012.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Atossa Therapeutics have?
Currently, no data Available
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.058. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in GB:0HJ7
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (― Downside)
$6.25 (― Downside)
Blogger Sentiment
Bullish
GB:0HJ7 Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.48%
12-Months-Change
Fundamentals
Return on Equity
-41.66%
Trailing 12-Months
Asset Growth
-24.86%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
0HJ7 Stock 12 Month Forecast
Average Price Target
$6.25
Options Prices
Currently, No data available
---